Article
Bristol Myers profit beats estimates on resilient Revlimid sales
Rating:
0.0
Views:
55
Likes:
1
Library:
1
Bristol Myers Squibb Co on Wednesday reported bigger second-quarter profit than expected as sales of its blockbuster cancer drug Revlimid did not drop as steeply as feared despite competition from generic drugs.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value